Encorafenib (Braftovi ™)
SELF ADMINISTRATION - ORAL
Indications for Prior Authorization:
Indicated in combination with Mektovi® (binimetinib tablets), for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA approved test.
The following criteria must be met:
Medication is prescribed by or in consultation with an oncologist, AND
Patient has unresectable, advanced, or metastatic melanoma, AND
Patient has melanoma with BRAF V600 mutation, AND
Braftovi will be used in combination with Mektovi® (binimetinib tablets)
450 mg (six 75 mg capsules) orally taken once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Last review date: August 27, 2019